Jun 12 |
SA58 reduced COVID-19 risk: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for cases. 3 studies (all from the same team) show significant benefit. Meta analysis using the most serious outcome reported shows 67% [17‑87%] lower risk. Results are better for Randomized Con.. | ||
Dec 31 2023 |
et al., China CDC Weekly, doi:10.46234/ccdcw2023.040 | Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study — Hohhot City, Inner Mongolia Autonomous Region, China, 2022 |
| 78% fewer cases (p=0.0001). Prospective study of 3,368 medical personnel in China showing significantly lower COVID-19 cases with SA58 nasal spray use. | ||
May 25 2023 |
et al., Emerging Microbes & Infections, doi:10.1080/22221751.2023.2212806 | Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study |
| 81% fewer symptomatic cases (p=0.0004) and 62% fewer cases (p=0.0001). RCT 1,222 healthy adult workers in China showing SA58 (anti-SARS-CoV-2 monoclonal antibody) nasal spray reduced symptomatic COVID-19 by 81% and SARS-COV-2 infection by 62% compared to placebo when used as post-exposure prophylaxis within .. | ||
Mar 20 2023 |
et al., medRxiv, doi:10.1101/2023.03.19.23287462 | Safety and Effectiveness of SA58 Nasal Spray against SARS-CoV-2 family transmission: an exploratory single-arm trial |
| 34% fewer cases (p<0.0001). Exploratory single-arm trial of 70 family contacts showing a protective effect of SA58 nasal spray against household SARS-CoV-2 transmission. The incidence of infection was 62.9% in the experimental group versus 94.8% in a contemporaneous.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.